Home
overview

 

  

SMi's Superbugs & Superdrugs Conference is now in it's 13th year.

Visit the 2011 event page

 


 
2009 Past Event Details:

 

Health systems and medical professionals throughout the world are confronting the challenge of drug resistant bacteria, with regular outbreaks and dozens of deaths a year from MRSA and C. difficile in first world hospitals; and the emergence of new challenges such as the USA:300 strain in San Fransisco. As the focus of the drug industry shifts back towards developing novel antibiotics, SMi’s 11th Annual Superbugs and Superdrugs conference will provide the perfect opportunity to assess the latest developments in this exciting field.

 

 

 

Our panel of leading experts from the pharma and biotech industries and

academia will look at key topics including:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  • Case studies of novel therapeutics for Helicobacter pylori

     

  • Developing new treatments for multi drug resistant TB

     

  • NCEs that target the challenge of gram positive bacteria

     

  • Clinical challenges in achieving regulatory approval, including paediatric trials

     

  • Pricing and reimbursement opportunities for antibiotics

     

  • New screening and detection technologies for drug resistant bacteria

     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Managers, Directors, and Vice Presidents working in:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  • Microbiology

     

  • Immunology

     

  • Infectious Diseases

     

  • Medicinal Chemistry

     

  • Clinical Pharmacology

     

  • Drug Discovery

     

  • New Product Development

     

  • Scientific Affairs

     

  • Licensing

     

  • Antibiotics

     

  • Infection Discovery

     

  • Drug evaluation

     

  • Molecular Biotechnology

     

  • Drug Development

     

  • Project Management

     

  • Preclinical Development

     

  • Portfolio Management

     

 

 

 

 

 

  

 

 

 

 

 

 

 

Last years attendees included representatives of the following companies:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  • Novo Nordisk

     

  • Plant Bioscience (PBL)

     

  • Leo Pharma

     

  • Summit

     

  • Arpida

     

  • Rib-X Pharmaceuticals

     

  • Enanta Pharmaceuticals

     

  • AstraZeneca

     

  • Intermed Discovery

     

  • Wockhardt

     

  • University Medical Centre Utrecht

     

  • Targanta Therapeutics

     

  • Cipan - Companhia Industiral Produtora De Antibioticos S A

     

  • Aquapharm Biodiscovery

     

  • Cilag Biotech

     

  • AM-Pharma

     

 

 

 

  • Enanta Pharmaceuticals

     

  • Bayer Healthcare

     

  • Boehringer Ingelheim

     

  • University of Oxford

     

  • Forest Laboratories

     

  • Dr Reddy's Laboratories

     

  • NOVEXEL

     

  • Novolytics

     

  • Destiny Pharma

     

  • IPSAT Therapies

     

  • Mutabilis SA

     

  • Intermed Discovery

     

  • Anacor Pharmaceuticals

     

  • Pfizer

     

  • Combinature Biopharma

     

  • Meiji Seika Kaisha Pharmaceuticals

     

 

 

 

 

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Nafsika Georgopapadakou

Nafsika Georgopapadakou, VP Research, NovaBay Pharmaceuticals

9:10 PARADISE LOST, PARADISE FOUND? THE CHANGING FORTUNES OF ANTIBACTERIAL DRUG DEVELOPMENT AND COMMERCIALISATION

Chris Thomson

Chris Thomson, Director, Business Development, Astellas Pharma Europe Ltd

  • Dynamics of antibacterial drug development and commercialisation
  • Current trends
  • Future pipeline and implications
  • 9:50 THE CHALLENGE OF PAEDIATRIC CLINICAL TRIALS

    David  McIntosh

    David McIntosh, Medical Director, Infectious Diseases, Wyeth

  • New regulation means that new medications need paediatric trials before registration
  • Regulatory requirements for a paediatric antibiotic trials
  • Preferable to begin trials early, but ethically questionable without sufficient data
  • Hurdles to implementing paediatric trials
  • Case study of a successful paediatric trial
  • 10:30 Morning Coffee

    11:00 “DELTA CREEP”: HOW TO AVOID IT

    Ronald GM Van Amsterdam

    Ronald GM Van Amsterdam, Principal Medical Scientist, Astellas Pharma Europe Ltd

  • Regulators are increasingly concerned by non-inferiority studies to progressively reduce efficacy
  • Choosing an appropriate comparator drug or placebo
  • Can improved trial design and tighter “delta” values can counter this problem?
  • Case study - data from the telavancin development programme
  • 11:40 ADDRESSING THE CHALLENGE OF FUNGAL INFECTIONS: WHAT ARE OUR OPTIONS?

    Nafsika Georgopapadakou

    Nafsika Georgopapadakou, VP Research, NovaBay Pharmaceuticals

  • Fungi such as Aspergillus fumigatus cause a variety of serious nosocomial infections in immunocompromised patients. 
  • As a result, their resistance to antibiotics has profound clinical implications. 
  • Only three antibiotic classes are currently in clinical use for fungal infections:  amphotericin, echinocandins and azoles. 
  • All three classes have efficacy and toxicity drawbacks, hence there is an urgent need to improve the existing antibiotic classes or introduce new classes altogether. 
  • Approaches towards achieving this include:
    - derivatization of echinocandins and azoles
    - potentiation by modulating resistance mechanisms targeting other fungal functions
    - and importing insights from antiprotozoal and anticancer agents. 
  • These different approaches will be discussed and examples of each will be given.
  • 12:20 Networking Lunch

    14:30 CASE STUDY OF THE DISCOVERY AND DEVELOPMENT OF A NOVEL ANTIBACTERIAL

    Albert Collinson

    Albert Collinson, Chief Business Officer, Rib - X - Pharmaceuticals Inc

  • Details to be confirmed
  • 15:10 Afternoon Tea

    15:40 DESTINY PHARMA: XF DRUGS: CREATING NEW APPROACHES TO OVERCOME BACTERIAL RESISTANCE

    Bill Love

    Bill Love, Chief Executive Officer, Destiny Pharma Ltd.

  • XF series – a new antimicrobial platform
  • Rapid bactericidal mode of action
  • Broad spectrum gram positive activity
  • MRSA: no resistance to XF73 after 55 passages
  • Drug development prospects – XF73 in phase II clinical trials
  • 16:20 HELICOBACTER PLYORI

    William Weiss

    William Weiss, Director of Pre-Clinical Services, University Of North Texas Health Science Center

  • Epidemiology and prevalence in the population
  • Scope and severity of the disease state
  • Diagnosis and detection of H. pylori
  • Target product profile of an effective agent(s)
  • Current and/or future treatment options and success
  • 17:00 WHAT YOU GET IS WHAT YOU RESEARCH FOR: FINALOFLOXACIN, A NOVEL PH ACTIVATED CLINICAL STAGE QUINOLONE

    Harald Labischinski

    Harald Labischinski, Managing Director, Merlion Pharmaceuticals

  • Helicobacter eradication: the medical need
  • Anti-infective indications characterised by a low pH environment: why is this important
  • Research goals and translation into a clinical candidate profile
  • What’s a pH activated quinolone?
  • Why developing a novel quinolone and for what indications?
  • Overview on preclinical and early clinical profile
  • 17:40 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Neil Ryder

    Neil Ryder, Executive Director, Novartis Institutes for Biomedical Research Inc.

    9:10 FINDING NOVEL TARGETS FOR ANTIMICROBIAL DISCOVERY

    Neil Ryder

    Neil Ryder, Executive Director, Novartis Institutes for Biomedical Research Inc.

  • Cheaper prices for antibiotics compared to oncology drugs creates a disincentive to invest
  • Emerging challenge of resistant infections
  • Increased government spending makes new potential in the market
  • 9:50 REPLACING CULTURE BASED MRSA SCREENING

    Richard James

    Richard James, Professor, University Of Nottingham

  • What diagnostic information is required to improve clinical outcomes
  • The currently available molecular diagnostic tests and their strengths and weaknesses
  • Moving diagnostic tests closer to the patient
  • What the new methods for whole genome sequencing can offer clinical microbiology
  • 10:30 Morning Coffee

    11:00 A NOVEL I.V. ANTIBACTERIAL AGENT FOR HOSPITAL ACQUIRED INFECTIONS

    Bozena Korczak

    Bozena Korczak, Vice President Drug Development, PolyMedix, Inc.

  • PMX-30063, a novel antibacterial currently in clinical trials
  • Case study of development – details to be confirmed
  • 11:40 DISCOVERY AND DEVELOPMENT OF NOVEL TARGETED AND BROAD SPECTRUM ANTIBACTERIALS

    David Haydon

    David Haydon, Director of Research, Prolysis

  • Anti-staphylococcal cell division inhibitors
  • Novel DNA supercoiling inhibitors
  • 12:20 Networking Lunch

    13:50 MARINE NATURAL PRODUCTS; A NEW & DIVERSE SOURCE OF PHARMACEUTICAL COMPOUNDS

  • Aquapharm’s business overview
  • Opportunity of marine chemistry as a novel pharmaceutical agents
  • Aquapharm’s current antimicrobial pipeline: development updates
  • Summary
  •  
  • Andrew Mearns Spragg

    Andrew Mearns Spragg, Chief Executive Officer, Aquapharm Biodiscovery Ltd

    14:30 ANTIMICROBIAL MECHANISMS IN INFLAMMATORY BOWEL DISEASE

    Scott Parkinson

    Scott Parkinson, Research Investigator, Novartis Institute of biomedical Research

  • Lead finding
  • Target and cell based screening
  • Case study – details to be confirmed
  • 15:10 Afternoon Tea

    16:20 ANTIBIOTIC TOLERANCE OF BACTERIAL BIOFILMS AND PERSISTER CELLS

    Alex O'Neill

    Alex O'Neill, Independent Research Fellow, University of Leeds

  • Research into antibiotic resistance has traditionally focused on discrete genetic determinants
  • However, bacteria are also able to resist a broad range of antibacterials by entering physiological states in which the action of these agents becomes attenuated, a phenomenon known as persistence or tolerance.
  • The persister state is poorly understood, although it is considered a primary reason for the prolonged antibacterial treatment that is required to eradicate many bacterial infections
  • The phenomenon of persistence is frequently encountered in bacterial biofilms - the primary mode of bacterial growth in many chronic infections
  • Infections involving a biofilm component are often extremely difficult to treat as a consequence of the extreme antibiotic tolerance exhibited by biofilm cells.
  • It is therefore apparent that further understanding of persistence is of key importance, both for improving fundamental knowledge of bacterial physiology and bacterial responses to inhibition, and for guiding future strategies in antibacterial chemotherapy.
  • 16:20 USING BACTERIOPHAGE TO COMBAT SUPERBUGS

    Nick Housby

    Nick Housby, Chief Executive Officer, Novolytics

  • Regulatory implications for bacteriophage
  • Topical and systemic applications of bacteriophage
  • Challenges in clinical development
  • Novolytics case study
  • Clinical trial progress
  • 17:00 Chairman’s Closing Remarks and Close of Conference

    +

    Workshops

    Anti-infective Drug Discovery and Development Workshop: Translating Innovation to Success
    Workshop

    Anti-infective Drug Discovery and Development Workshop: Translating Innovation to Success

    Crowne Plaza Hotel - St James
    17th March 2009
    London, United Kingdom

    Crowne Plaza Hotel - St James

    Buckingham Gate 45/51
    London SW1E 6AF
    United Kingdom

    Crowne Plaza Hotel - St James

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.